{'Year': '2012', 'Month': 'Jun'}
Pharmacogenomics of third-generation aromatase inhibitors.
Breast cancer is a common, life-threatening disease among women. Contemporary hormonal therapy with third-generation aromatase inhibitors for estrogen-receptor-positive breast cancers in postmenopausal women is still facing the challenge of interpatient variability in therapeutic response and intensity of adverse effects.